Follow-On Biologic Stakeholders Agree On Patent Resolution, Differ On Details
Executive Summary
Inclusion of a mechanism for patent dispute resolution in the pathway for approving follow-on biologics was supported by representatives on both sides of the FOB debate during a Federal Trade Commission workshop Nov. 21
You may also be interested in...
Waxman To Seek Consensus On FOBs, Incentives For Early Patent Resolution
Efforts will be made "over the next few months" to bring House Energy and Commerce Committee members to a consensus on a follow-on biologics bill, according to committee staffer Ann Witt
Waxman To Seek Consensus On FOBs, Incentives For Early Patent Resolution
Efforts will be made "over the next few months" to bring House Energy and Commerce Committee members to a consensus on a follow-on biologics bill, according to committee staffer Ann Witt
Biosimilars Should Face Patent Challenges Only After Approval, Novartis Says
Linking patent disputes to regulatory approval of follow-on biologics would provide no competitive benefit for patients and could discourage innovation, contends Robert Pelzer, head of Novartis' North American operations